Posted on

Tryp Therapeutics To Present At 15th Annual Pain Therapeutics Summit

Tryp Therapeutics To Present At 15th Annual Pain Therapeutics Summit

SAN DIEGO – Oct. 26, 2021 – Tryp Therapeutics (CSE:TRYP; OTCQB:TRYPF) (“Tryp” or the “Company”), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that the Company will present at the 15th Annual Pain Therapeutics Summit on November 1, 2021 at 12:15 p.m. EDT.

The virtual conference will take place on November 1-3, 2021. Greg McKee, Chairman and CEO, will provide an overview of the Company followed by a live Q&A session with emphasis on the chronic pain indications that Tryp is pursuing including fibromyalgia, phantom limb pain, and complex regional pain syndrome (CRPS).

PRESENTATION DETAILS FOR TRYP THERAPEUTICS

Date: November 1, 2021
Time: 12:15 p.m. EDT
Registration: Available here

About Tryp Therapeutics

Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-For-Neuropsychiatric Disorders (PFN™) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of chronic pain and other indications. The Company has announced upcoming Phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and overeating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and route of administration to improve the patient experience. For more information, please visit www.tryptherapeutics.com.

Investor Inquiries:
Joseph Green
Edison Group
investors@tryptherapeutics.com

Media Inquiries:
Joy Willis
Tryp Therapeutics
media@tryptherapeutics.com
1-833-811-8797

Forward-Looking Information

Certain information in this news release constitutes forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans,” “targets,” “expects” or “does not expect,” “is expected,” “an opportunity exists,” “is positioned,” “estimates,” “intends,” “assumes,” “anticipates” or “does not anticipate” or “believes,” or variations of such words and phrases or state that certain actions, events or results “may,” “could,” “would,” “might,” “will” or “will be taken,” “occur” or “be achieved.” In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the “Risk Factors” section of Tryp’s final prospectus available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Posted on

Mindset Pharma to Participate in Wonderland: Miami on November 8-9, 2021

Mindset Pharma to Participate in Wonderland: Miami on November 8-9, 2021

TORONTO, Oct. 26, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet medical needs, today announced that it will participate in Microdose’s Wonderland: Miami to be held at the Adrienne Arsht Center for the Performing Arts in Miami, FL on November 8-9, 2021.

James Lanthier, CEO of Mindset, and Joseph Araujo, CSO of Mindset will give a presentation titled Beyond Psilocybin: New Frontiers in Psychedelic Drug Design on Monday, November 8th at 12:45 p.m. ET. Register to attend here.

For more information about the event, or to schedule a one-on-one meeting with Mindset’s management team, please contact KCSA Strategic Communications at MindSet@kcsa.com.

About Mindset Pharma
Mindset Pharma Inc. is a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs. Mindset was established in order to develop next generation pharmaceutical assets that leverage the breakthrough therapeutic potential of psychedelic drugs. Mindset is developing several novel families of next generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin as well as its own proprietary compounds.

For further information on Mindset, please visit our website at www.mindsetpharma.com.

For more information, please contact:

Investor Contact:
Allison Soss/Tim Regan
KCSA Strategic Communications
Email: MindSet@kcsa.com
Phone: 212-896-1267/ 347-487-6788

Company Contact:
James Lanthier, CEO
Email: jlanthier@mindsetpharma.com

Jason Atkinson, VP, Corporate Development
Email: jatkinson@mindsetpharma.com
Phone: 416-479-4094

‍Forward-Looking Information

This news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward looking information is frequently characterized bywords such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “would”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Forward-looking information is based on the opinions and estimates of management at the date the information is provided and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Additional information regarding risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s annual information form for the financial year ended June 30, 2020 dated March 5, 2021. The forward-looking information included in this news release is made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information to reflect new information, subsequent events or otherwise, except as required by applicable law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Posted on

The largest psychedelic event in history

The Largest Psychedelic Medicine Business Event, Ever Wonderland: Miami

Curious about the latest advancements in psychedelic medicine, psychedelic retreats, microdosing, or the role of technology in the psychedelics sector? Then you won’t want to miss Microdose HQ’s Wonderland: Miami – the largest event psychedelic medicine business event to date!

The two-day event on Nov. 8-9 will have keynote presentations from some of the biggest names in the psychedelic sector including including Robin Carhart-Harris, Matthew W. Johnson, Rick Doblin, and David Nutt. Mike Tyson and Lamar Odon will also share their experiences with psychedelic healing.

The speakers will cover a huge range of unique topics such as Shamanic protocols for making investment decisions, psychedelics and sports, and the threat of corporate domination of the industry. Get your your ticket or virtual access pass here!

 

Posted on

Brittany Hoogenboom To Headline At Meet Delic in November

Brittany Hoogenboom To Headline At Meet Delic in November

Brittany Hoogenboom, Founder of Synergy Soul and Holistic Business Coach, To Headline At Meet Delic: 

The World’s Premiere Psychedelic and Wellness Event

Meet Delic, the revolutionary, two-day immersive edutainment experience for the world’s leading psychedelic and wellness thought and business leaders will take place at AREA15 in Las Vegas, Nevada, November 6 – 7, 2021

Vancouver, BC, October 19, 2021 – Delic Holdings Corp (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source) the leading psychedelic wellness platform, today announced that Brittany Hoogenboom will serve as a keynote speaker at Meet Delic on November 7. Hoogenboom is the founder and owner of Synergy Soul, a brand focused on personal transformation through a holistic, integrated approach to life, business and wealth. She is also a certified physical therapy assistant, yoga instructor, and reiki master.

Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, wellness, and business with like-minded visionaries. Hoogenboom’s keynote, Mind, Body, Soul & Business, will explore looking at money and business in a holistic manner and how the practical and energetic aspects work together to create sustainable wealth and business longevity.

“To be able to be a part of a revolutionary movement, such as Meet Delic, from the beginning is a gift that will keep on giving,” said Hoogenboom. “The businesses and people who are part of this event are the ones who are making moves in this world for the betterment of all people. We are revolutionaries and leaders of our time.”

Meet Delic is committed to bringing awareness of the science-backed benefits of psychedelics and business opportunities to the mainstream and larger global community by reframing the psychedelic conversation. The experiential event will feature dancers, music, 3D-mapping, visual artists, new technologies and research, thought-provoking presentations and one of the world’s largest psychedelic business expo.

“We are very excited to have Brittany’s fresh voice and approach to personal transformation at Meet Delic,” said Delic co-founder, Jackee Stang. “She has a unique way of integrating health, wellness, spirituality and business, and I believe our attendees will gain valuable insight and knowledge from her experience.”

The twenty hours of panels and keynotes will include an array of topics such as Accelerating Adaptation: What Psychedelic States can teach us about Healing, Aphrodisiacs and Psychedelics: A History of Medicine for Love, Fentanyl in our Drugs, Ketamine: An Intimate Discussion on the New Wonder Drug for PTSD, Deciphering the Medical Potential of Psychedelics, A Discussion with George Goldsmith & Ekaterina Malievskaia featuring Clara Burtenshaw, Psychedelics and Futurism.

Tickets are now available for the two-day experience. For more information please visit, meetdelic.com. Follow us on @meetdelic on Instagram, Twitter and Facebook. Tickets available now.

Meet Delic is a subsidiary of Delic, which is focused on bringing psychedelic wellness to the mainstream. The company does this through an umbrella of related owned and operated businesses to support scaling the impact and reach of treatment, including 1) trusted media and e-commerce platforms and in-person events like Meet Delic to market the services directly to patients and consumers and gain data, 2) a licensed lab to develop IP, R&D and innovative high quality and safe product lines and 3) the largest and most accessible network of physical clinics to administer effective treatments.

   ###

About Meet Delic

Meet Delic is the world’s premier psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Held in AREA15, an immersive and experiential entertainment complex in the heart of Las Vegas, the exciting two-day event features industry entrepreneurs, consumers, psychonauts and leading voices in research and science. Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, health and wellness and culture, how to start or grow your business, connect with likeminded visionaries, enjoy fun social activities, and experience the acceleration of this worldwide movement. 

About Delic Corp

Delic is the leading psychedelic wellness platform, committed to addressing the mental health crisis by increasing access to science-backed benefits for all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including Reality Sandwich and Delic Radio, trusted media and e-commerce platforms; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premier psychedelic wellness event; and the largest chain of psychedelic wellness clinics in the country with Ketamine Infusion Centers and Ketamine Wellness Centers (pending acquisition). Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of

this release.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Delic’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”.

By identifying such information and statements in this manner, Delic is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Delic to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Delic has made certain assumptions.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although Delic believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Delic does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this notice.

SOURCE Delic Holdings Inc.
Media & Investor Inquiries: Rich Rodriguez, rich@deliccorp.com

Posted on

KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing

KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing

Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations

NEW YORK, Oct. 18, 2021 /CNW/ – Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the presentations from the KCSA Psychedelics Virtual Investor Conference are now available for on-demand viewing.

REGISTER OR LOGIN NOW AT: https://bit.ly/3acCV7Y

The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download shareholder materials from the company’s “virtual trade booth”.

Presentations

Presentation

Ticker(s)

Fireside Chat – Amy Emerson, CEO of MAPS Public Benefit Corporation

“Investing in Psychedelics and CNS Treatments”

       Lindsay Hoover, Partner, JLS Fund

       Dan Ahrens, PM of the Psychedelics ETF (NYSEArca: PSIL), AdvisorShares Investments

       Tim Regan, SVP, KCSA Strategic Communications

Small Pharma Inc.

(Pink: DMTTF | TSX-V: DMT)

Awakn Life Sciences Corp.

(OTCQB: AWKNF | NEO: AWKN)

HMNC Brain Health

(Private Company)

Enveric Biosciences

(NASDAQ: ENVB)

Mind Cure Health Inc.

(OTCQX: MCURF | CSE: MCUR)

Field Trip Health Ltd.

(NASDAQ: FTRB |TSX: FTRP)

Novamind Inc.

(OTCQB: NVMDF | CSE: NM)


BetterLife Pharma Inc.

(OTCQB: BETRF | CSE: BETR)

MYND Life Sciences Inc.

(Pink: MYNDF | CSE: MYND)

FSD Pharma Inc.

(NASDAQ: HUGE | CSE: HUGE)

Mindset Pharma Inc.

(OTCQB: MSSTF | CSE: MSET)

PsyBio Therapeutics Corp.

(OTCQB: PSYBF | TSX-V: PSYB)

Psyched Wellness Ltd.

(OTCQB: PSYCF | CSE: PSYC)

Bright Minds Biosciences Inc.

(OTCQB: BMBIF | CSE: DRUG)

Cybin Inc.

(NYSE American: CYBN | NEO: CYBN)


Mydecine Innovations Group

(Pink: MYCOF | NEO: MYCO)

NeonMind Biosciences Inc.

(OTCQB: NMDBF | CSE: NEON)

Numinus Wellness Inc.

(TSX-V: NUMI)

Tryp Therapeutics Inc.

(OTCQB: TRYPF | CSE: TRYP)

Wesana Health Holdings Inc.

(OTCQB: WSNAF | CSE: WESA)

Filament Health Corp.

(OTCQB: FLHLF | NEO: FH)

To facilitate investor relations scheduling, please contact KCSA Strategic Communications a conference@kcsa.com.

About Virtual Investor ConferencesSM
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly-traded companies to meet and present directly with investors.

A real-time solution for investor engagement, Virtual Investor Conferences is part of OTC Market Group’s suite of investor relations services specifically designed for more efficient Investor Access.  Replicating the look and feel of on-site investor conferences, Virtual Investor Conferences combine leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.

To learn more about VIC and view a complete calendar of events, please visit www.virtualinvestorconferences.com.

About KCSA Strategic Communications
KCSA is a fully integrated communications agency specializing in public relations, investor relations and social media, with expertise in financial and professional services, technology, healthcare, digital media and cannabis. Since 1969, the firm has demonstrated strategic thinking and program execution that drives results for its clients in the ever-changing communications and digital landscape. The firm’s clients are its best references. For more information, please visit www.kcsa.com.

SOURCE VirtualInvestorConferences.com

For further information: Media Contact: OTC Markets Group Inc., (212) 896-4428, media@otcmarkets.com; Investor Contacts: John M. Viglotti, SVP Corporate Services, Investor Access, OTC Markets Group, (212) 220-2221, johnv@otcmarkets.com; Tim Regan/Allison Soss, KCSA Strategic Communications,(212) 682-6300, conference@kcsa.com

Posted on

Duncan Trussell, Actor, Stand-Up Comedian & Host of the Duncan Trussell Family Hour Podcast, To Keynote At Meet Delic

Duncan Trussell, Actor, Stand-Up Comedian & Host of the Duncan Trussell Family Hour Podcast, To Keynote At Meet Delic

Duncan Trussell, Actor, Stand-Up Comedian & Host of the Duncan Trussell Family Hour Podcast, To Keynote At Meet Delic:

The World’s Premiere Psychedelic and Wellness Event

World’s leading experts and thought leaders on psychedelics and wellness to gather for a two-day immersive edutainment experience at AREA15 in Las Vegas, Nevada, November 6 – 7, 2021

Vancouver, BC, October 12, 2021 – Delic Holdings Corp (“Delic” or the “Company”) (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) (Original Source) the leading psychedelic wellness platform, today announced that Duncan Trussell will serve as a keynote speaker at Meet Delic on November 6. Trussell is an actor who co-created and appears in the Netflix animated series The Midnight Gospel. He also hosts the Duncan Trussell Family Hour podcastand regularly travels the country performing stand-up comedy at festivals and shows.

Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, wellness, and business with like-minded visionaries. Trussell’s keynote will be a live taping of the Duncan Trussell Family Hour podcast, a weekly salon-style supershow where he and his guests explore the outer reaches of the multiverse. The show is ranked as one of the top 25 comedy podcasts on the Apple Podcast app.

“Duncan is one of those special people who has many talents and excels at all of them,” said Delic co-founder, Jackee Stang. “We are honored and excited to have him host his popular podcast live from the conference so attendees can join in on the fun!”

Meet Delic is committed to bringing awareness of the science-backed benefits of psychedelics and business opportunities to the mainstream and larger global community by reframing the psychedelic conversation. The experiential event will feature dancers, music, 3D-mapping, visual artists, new technologies and research, thought-provoking presentations and one of the world’s largest psychedelic business expo.

The twenty hours of panels and keynotes will include an array of topics such as “Why Are Psychedelics Medicine?”, “How Big Money is (Already) Playing Psychedelics,” “PTSD Reset and Recovery,” “Psychedelics & Addiction: an Intimate Discussion on Recovery in a Modern World,” “Ketamine Clinics Today, Psilocybin and MDMA Therapy Tomorrow,” “Microdosing,” “Psychedelic Activism,” “Aphrodisiacs and Psychedelics: A History of Medicine for Love”, “How Psychedelics Can be Effectively Used for Physical Optimization,” and “Drug Use for Grown-Ups.” Musical and entertainment acts are scheduled both evenings following the panels and expo.

Tickets are now available for the two-day experience. For more information please visit, meetdelic.com. Follow us on @meetdelic on Instagram, Twitter and Facebook. Tickets available now.

Meet Delic is a subsidiary of Delic, which is focused on bringing psychedelic wellness to the mainstream. The company does this through an umbrella of related owned and operated businesses to support scaling the impact and reach of treatment, including 1) trusted media and e-commerce platforms and in-person events like Meet Delic to market the services directly to patients and consumers and gain data, 2) a licensed lab to develop IP, R&D and innovative high quality and safe product lines and 3) the largest and most accessible network of physical clinics to administer effective treatments.

          ###

About Meet Delic

Meet Delic is the world’s premier psychedelic and wellness edutainment event catering to both curious newcomers, businesses and thought leaders. Held in AREA15, an immersive and experiential entertainment complex in the heart of Las Vegas, the exciting two-day event features industry entrepreneurs, consumers, psychonauts and leading voices in research and science. Meet Delic is the largest and most comprehensive event to learn about the intersection of psychedelics, health and wellness and culture, how to start or grow your business, connect with likeminded visionaries, enjoy fun social activities, and experience the acceleration of this worldwide movement.

About Delic Corp

Delic is the leading psychedelic wellness platform, committed to bringing science-backed benefits to all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including trusted media and e-commerce platforms like Reality Sandwich and Delic Radio, Delic Labs the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology, Meet Delic the premiere psychedelic wellness event, and Ketamine Infusion Centers one of the largest ketamine clinics in the country. Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products, and treatment options to the masses.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and does not accept responsibility for the adequacy or accuracy of

this release.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Delic’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”.

By identifying such information and statements in this manner, Delic is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Delic to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Delic has made certain assumptions.

Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although Delic believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Delic does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to Delic or persons acting on its behalf is expressly qualified in its entirety by this notice.

SOURCE Delic Holdings Inc.

Investor Inquiries: Daniel Southan-Dwyer, dsd@deliccorp.com

Media Inquiries: Rich Rodriguez, rich@deliccorp.com

Posted on

Tryp Therapeutics To Present At The Kcsa Psychedelics Virtual Investor Conference

Tryp Therapeutics To Present At The Kcsa Psychedelics Virtual Investor Conference

San Diego, California–(Newsfile Corp. – October 12, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company“), a pharmaceutical company developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it will present at the KCSA Psychedelics Virtual Investor Conference on October 14, 2021 at 3:00 p.m. EDT.

The conference will be held virtually on October 13-14, 2021. Luke Hayes, Chief Financial Officer, will provide a live overview of Tryp’s activities and elaborate on how the Company is leading the next wave of psychedelic drug development beyond mental health with its focus on chronic pain and other indications.

PRESENTATION DETAILS FOR TRYP THERAPEUTICS

Date: October 14, 2021
Time: 3:00 p.m. EDT
Registration: Available here

About Tryp Therapeutics

Tryp Therapeutics is a pharmaceutical company focused on developing psilocybin-based compounds for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-For-Neuropsychiatric Disorders (PFN™) program is focused on the development of synthetic psilocybin as a new class of drug for the treatment of chronic pain and other indications. The Company has announced upcoming Phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and overeating disorders, respectively. Tryp is also developing a proprietary psilocybin-based product, TRP-8803, that uses a novel formulation and route of administration to improve the patient experience. For more information, please visit www.tryptherapeutics.com.

Investor Inquiries:
Joseph Green
Edison Group
investors@tryptherapeutics.com

Media Inquiries:
Joy Willis
Tryp Therapeutics
media@tryptherapeutics.com
1-833-811-8797

Forward-Looking Information

Certain information in this news release constitutes forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans,” “targets,” “expects” or “does not expect,” “is expected,” “an opportunity exists,” “is positioned,” “estimates,” “intends,” “assumes,” “anticipates” or “does not anticipate” or “believes,” or variations of such words and phrases or state that certain actions, events or results “may,” “could,” “would,” “might,” “will” or “will be taken,” “occur” or “be achieved.” In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Tryp as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in greater detail in the “Risk Factors” section of Tryp’s final prospectus available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect Tryp; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and Tryp expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Posted on

KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th

KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th

Psychedelic and CNS Company Executives share vision, answer questions live at VirtualInvestorConferences.com 

NEW YORK, Oct. 11, 2021 /CNW/ – Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the agenda for the upcoming KCSA Psychedelics Virtual Investor Conference. Individual investors, institutional investors, advisors, and analysts are invited to attend the two-day program beginning Wednesday, October 13, 2021, at 9:45 a.m. ET.

“The psychedelics industry is poised to provide much needed therapies to address the global mental health crisis. Some of the companies presenting over the next two days may be the next Pfizer, Roche or Sanofi,” commented Lewis Goldberg, Managing Partner at KCSA Strategic Communications.

REGISTER NOW AT: https://bit.ly/3acCV7Y

It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There are no fees to log-in, attend the live presentations or ask questions.

October 13th Agenda:  

Eastern
Time (ET)

Presentation

Ticker(s)

9:45 AM

KCSA Welcome Remarks

10:00 AM

Small Pharma Inc.

(Pink: DMTTF | TSX-V: DMT)

10:30 AM

Awakn Life Sciences Corp.

(OTCQB: AWKNF | NEO: AWKN)

11:00 AM

HMNC Brain Health

(Private Company)

11:30 AM

Enveric Biosciences

(NASDAQ: ENVB)

12:00 PM

Mind Cure Health Inc.

(OTCQX: MCURF | CSE: MCUR)

12:30 PM

Field Trip Health Ltd.

(NASDAQ: FTRB)

1:00 PM

Novamind Inc.

(OTCQB: NVMDF | CSE: NM)

1:30 PM


BetterLife Pharma Inc.

(OTCQB: BETRF | CSE: BETR)

2:00 PM

MYND Life Sciences Inc.

(Pink: MYNDF | CSE: MYND)

October 14th Agenda:

Eastern
Time (ET)

Presentation

Ticker(s)

9:55 AM

KCSA Opening Remarks

10:00 AM

Mindset Pharma Inc.

(OTCQB: MSSTF | CSE: MSET )

10:30 AM

PsyBio Therapeutics Corp.

(OTCQB: PSYBF | TSX-V: PSYB)

11:00 AM

Psyched Wellness Ltd.

(OTCQB: PSYCF | CSE: PSYC)

11:30 AM

Bright Minds Biosciences Inc.

(OTCQB: BMBIF | CSE: DRUG)

12:00 PM ET

Fireside Chat – Amy Emerson, CEO of MAPS Public Benefit Corporation

12:30 PM ET

Lunch Panel – Hosted by KCSA’s Tim Regan “Investing in Psychedelics and CNS Treatments”

1:00 PM

Cybin Inc.

(NYSE American: CYBN | NEO: CYBN)

1:30 PM


Mydecine Innovations Group

(Pink: MYCOF | NEO: MYCO)

2:00 PM

NeonMind Biosciences Inc.

(OTCQB: NMDBF | CSE: NEON)

2:30 PM

Numinus Wellness Inc.

(TSX-V: NUMI)

3:00 PM

Tryp Therapeutics Inc.

(OTCQB: TRYPF | CSE: TRYP)

3:30 PM

Wesana Health Holdings Inc.

(OTCQB: WSNAF | CSE: WESA)

4:00 PM

Filament Health Corp.

(Pink: FLHLF | NEO: FH)

To facilitate investor relations scheduling, please contact KCSA Strategic Communications a conference@kcsa.com.

About Virtual Investor ConferencesSM
Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly-traded companies to meet and present directly with investors.

A real-time solution for investor engagement, Virtual Investor Conferences is part of OTC Market Group’s suite of investor relations services specifically designed for more efficient Investor Access.  Replicating the look and feel of on-site investor conferences, Virtual Investor Conferences combine leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.

To learn more about VIC and view a complete calendar of events, please visit www.virtualinvestorconferences.com.

About KCSA Strategic Communications
KCSA is a fully integrated communications agency specializing in public relations, investor relations and social media, with expertise in financial and professional services, technology, healthcare, digital media and cannabis. Since 1969, the firm has demonstrated strategic thinking and program execution that drives results for its clients in the ever-changing communications and digital landscape. The firm’s clients are its best references. For more information, please visit www.kcsa.com.

SOURCE VirtualInvestorConferences.com

For further information: Media Contact: OTC Markets Group Inc., (212) 896-4428, media@otcmarkets.com; Investor Contacts: John M. Viglotti, SVP Corporate Services, Investor Access, OTC Markets Group, (212) 220-2221, johnv@otcmarkets.com; Tim Regan/Allison Soss, KCSA Strategic Communications, (212) 682-6300, conference@kcsa.com

Posted on

Novamind to Present at LD Micro and KCSA Conferences

Novamind to Present at LD Micro and KCSA Conferences

TORONTO, ON / October 8, 2021 / Novamind Inc. (CSE: NM | OTCQB: NVMDF | FSE: HN2) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, today announced participation in two upcoming virtual investor conferences on Wednesday, October 13, 2021.

Novamind’s CEO and Director, Yaron Conforti, will present the Company’s progress towards expanding access to psychedelic medicine in the U.S., including the recent opening of the Company’s sixth clinic and the newly launched Psychedelic Palliative Care program.

Virtual LD Micro Main Event XIV
Date: October 13, 2021
Time: 10:30 AM to 11:00 AM EST
Register and watch live here: me21.mysequire.com

KCSA Psychedelics Virtual Investor Conference
Date: October 13, 2021
Time: 1:00 PM to 1:30 PM EST
Register and watch live here: www.virtualinvestorconferences.com/events/event-details/psychedelics-virtual-investor-conference

About Novamind
Novamind is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit novamind.ca.

Contact Information
Novamind
Yaron Conforti, CEO and Director
Telephone: +1 (647) 953 9512

Samantha DeLenardo, VP, Communications
Email: media@novamind.ca

Bill Mitoulas, Investor Relations
Email: bill@novamind.ca

Forward-Looking Statements
This news release contains forward-looking statements. All statements other than statements of historical fact included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations including the risks detailed from time to time in the Company’s public disclosure. The reader is cautioned not to place undue reliance on any forward-looking information. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable laws.

Posted on

MINDCURE to Webcast Live at the KCSA Psychedelics Virtual Investor Conference on October 13, 2021

MINDCURE to Webcast Live at the KCSA Psychedelics Virtual Investor Conference on October 13, 2021

MINDCURE invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com

VANCOUVER, BC, Oct. 7, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research for psychedelics, today announced that President & Chief Executive Officer, Kelsey Ramsden will present virtually at the KCSA Psychedelics Investor Conference on Wednesday, October 13, 2021, which will be held at VirtualInvestorConferences.com.

DATE: October 13, 2021
TIME: 12:00pm ET
LINK: https://bit.ly/3kObcQO

This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event. It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.

Learn more about the event at www.virtualinvestorconferences.com.

About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on LinkedIn, Facebook, Twitter, and Instagram.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information
Certain information presented in this news release may constitute “forward-looking information” within the meaning of applicable securities laws regarding MINDCURE and its business. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases.

Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; the Company will develop its products as expected and that they will attain the outcomes anticipated; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that strategic partnerships entered by the Company will create the opportunities and outcomes anticipated; that MINDCURE will advance wellness worldwide; that trading on the OTCQX will attract additional investment and provide additional liquidity for shareholders.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information inherently entails known and unknown risks and uncertainties about the future and actual results and involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: trading on the OTCQX enhancing the visibility of MINDCURE and its strategic growth objectives to a larger subset of the investment community, while materially increasing its share liquidity and capturing additional capital markets attention to facilitate growth initiatives and deliver long-term shareholder value. Although MINDCURE has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.

Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and MINDCURE does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

For further information: MINDCURE Investor Relations, investors@mindcure.com, 1-888-593-8995; Media Inquiries, Annie Graf / Kristin Cwalinski, KCSA Strategic Communications, mindcure@kcsa.com